Shanghai Fosun Pharmaceutical, a biopharmaceutical and healthcare company, plans to develop its drug manufacturing and R&D capacity by acquiring Gland Pharma, an Indian pharmaceutical company.

The sale consideration is estimated to be between $1bn and $1.5bn.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Pfizer has announced that it will acquire Anacor Pharmaceuticals to expand and strengthen its business and develop atopic dermatitis, inflammation and immunology portfolio. The consideration is expected to be approximately $5.2bn.

It has further announced that following the acquisition, Quattro Merger, a wholly-owned subsidiary of Pfizer will be merged into Anacor, which will be a new wholly-owned subsidiary of Pfizer.

"Pfizer has announced that it will acquire Anacor Pharmaceuticals to expand and strengthen its business and develop atopic dermatitis, inflammation and immunology portfolio."

Centerview Partners and Guggenheim Securities are acting as financial advisors, while Wachtell, Lipton, Rosen & Katz are acting as legal advisors to the acquirer.

See Also:

Citigroup Inc. is acting as financial advisor and Davis Polk & Wardwell are acting as legal advisors for the target company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Luminex has entered a definitive agreement to acquire Nanosphere to accelerate its growth in new markets and develop its pipeline products and product portfolio.

The sale consideration is expected to be approximately $83m, which will be totally funded by Luminex through cash in hand.

Perella Weinberg Partners is acting as financial advisor and Gambell & Russell is acting as outside counsel to Luminex, while Jefferies LLC is acting as financial advisor and Seyfarth Shaw is acting as outside counsel to Nanosphere.

The transaction is expected to be completed by July 2016.